No Data
No Data
No Data
No Data
No Data
AtriCure Upgraded at Oppenheimer on Valuation
Seeking AlphaApr 23 20:34
AtriCure Raised to Outperform From Perform by Oppenheimer
AtriCure Raised to Outperform From Perform by Oppenheimer
Dow JonesApr 23 19:51
Oppenheimer: The AtriCure (ATRC.US) rating was raised from Perform to be superior to the market rating. The target price was $32.00.
Oppenheimer: The AtriCure (ATRC.US) rating was raised from Perform to be superior to the market rating. The target price was $32.00.
Zhitong FinanceApr 23 19:41
Oppenheimer Upgrades AtriCure to Outperform, Announces $32 Price Target
Oppenheimer analyst Suraj Kalia upgrades AtriCure from Perform to Outperform and announces $32 price target.
Analyst UpgradesApr 23 19:40
AtriCure Launched CryoSPHERE+ Cryoablation Probe To Reduce Freeze Times By 25% Vs. AtriCure's Legacy CryoSPHERE Device. The Product Is Currently In An Extended Limited Launch Period In US, With Full Launch Expected By The End Of Q2
AtriCure Launched CryoSPHERE+ Cryoablation Probe To Reduce Freeze Times By 25% Vs. AtriCure's Legacy CryoSPHERE Device. The Product Is Currently In An Extended Limited Launch Period In US, With Full L
BenzingaApr 18 20:08
AtriCure Announces Launch of the CryoSPHERE+ Probe for Post-Operative Pain Management
AtriCure, Inc. ((
BusinesswireApr 18 20:00
No Data
No Data